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Abstract Anxiety and depressive disorders are charac-
terized by a number of clinical symptoms like decreased
mood, apathy, anhedonia and anxiety. An important ele-
ment of the clinical picture is also neurocognitive impair-
ment. The most common treatment methods for depression
and anxiety are pharmacology, psychotherapy or a com-
bination of both methods. The data from literature show
that those treatment methods lead to an improvement of
clinical symptoms, but they exert a possible impact on
cognitive functions. However the study results referring
both to the role of pharmacological treatment and psy-
chotherapy in this domain are still inconsistent. There is an
increasing number of accessible data confirming the posi-
tive effects of those clinical interventions on cognitive
functioning of anxiety and depressive patients, but the
interpretation is complicated because of differences in
methodology as well as examined sample size and their
characteristics. More studies are then needed to describe
this phenomenon.
Keywords Pharmacotherapy  Psychotherapy 
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Introduction
Cognitive impairment is an important element of the
clinical picture of psychiatric diseases which requires
appropriate treatment and rehabilitation. According to
neuropsychological literature it is defined as a decline in
function in one or more domains of cognitive function. It
may represent a single deficit which is highly specific or a
cluster of deficits related to each other (Lezak et al. 2004).
It is being discussed by experts, what should be the role of
cognitive deficits in the diagnostic systems, and how they
can discriminate such disorders like schizophrenia and
affective disorders (Bora et al. 2010).
Cognitive deficits in depression
Traditional studies of unipolar depression and anxiety
disorders focus on typical symptoms like decreased mood,
apathy, anhedonia and anxiety but they do not pay suffi-
cient attention to the cognitive functioning of the patients.
Cognitive impairment may produce serious alteration in
daily functioning. Cognitive deficits in major depressive
disorder (MDD) in such domains as working memory,
attention, and psychomotor processing speed are consis-
tent, replicable, nonspecific, and clinically significant.
They are regarded to be responsible for psychosocial
impairment (McIntyre et al. 2013). Deficits in memory and
decision-making are supposed to be present early in the
course of the disease (Trivedi and Greer 2014). They are
observed already in the first episode. Psychomotor speed
and memory functioning are found to be associated with
clinical state. Attention and deficits in executive function-
ing are regarded to be trait elements of MDD (Lee et al.
2012). In studies referring to euthymic depressive patients
K. Krysta (&)  M. Krzystanek  I. Krupka-Matuszczyk
Department of Psychiatry and Psychotherapy, Medical




Department of Child and Adolescent Psychiatry and
Psychotherapy, Medical University of Silesia, ul. Zapolskiej 3,
41-218 Sosnowiec, Poland
A. Klasik
Institute of Psychology, University of Opole, Plac Staszica 1,
45-052 Opole, Poland
123
J Neural Transm (2015) 122 (Suppl 1):S101–S110
DOI 10.1007/s00702-014-1282-3
it was found that certain cognitive deficits like verbal
memory, speed of information processing and some exec-
utive functions are persistent even during remissions (Bora
et al. 2013). The study of Schaub et al. (2013) suggests that
the most common deficits in this domain present in
depressed patients relate to verbal and visual short-term
memory, verbal fluency, visual-motor coordination, infor-
mation processing in visual-verbal functioning and selec-
tive attention, however the results were not compared with
healthy controls. Problems with attention and memory refer
to the diagnostic criteria of depression and the patient’s
stopping to meet the criteria of depressive episode does not
imply the cognitive symptoms to disappear. It was sum-
marized by Roiser and Shakian (2013) that cognitive
impairment non-related to emotional state is present in
unipolar depression patients and that it tends to maintain
even after the remission from a depressive episode.
Moreover, the preserved cognitive impairment predicts
poor response to the treatment with antidepressants. The
relation between cognitive impairment in depression and
the disease itself is not established. As reviewed by Goe-
ldner et al. (2013), the cognitive deficit in depression seems
incorporated in the body of depressive process, however in
some subsets of the patients suffering from MDD, the
intensity of cognitive impairment does not relate to the
severity of depressive symptoms. The cognitive impair-
ment is also present in patients who maintain residual
symptoms of depression like fatigue, apathy and feeling a
little low mood. The study of Pedrelli et al. (2010) showed
that fatigue and feeling ‘‘blue’’ correlate with preservation
of specific cognitive problems like difficulties in concen-
tration and alertness. In the study of Gualtieri et al. (2006)
the cognitive impairment, occurring during the depressive
episode improved after the treatment with antidepressive
drug but was not normalized. Apart from the concept of the
two separated notions, different neuropsychlogical and
some new neuroimagining studies (e.g. Pu et al. 2011)
accumulate the evidence of the biological link between
depression and the impairment of the cognition. One of the
proposals, explaining problems in cognition among
depressive patients is the depression-executive dysfunction
(DED) model. According to DED model, the impairment
of cognitive functioning, especially the executive func-
tions, is likely to result in the poor response to antide-
pressants. However, due to the insufficient number of
studies the hypothesis cannot be validated so far (McLen-
nan and Mathias 2010).
Another issue raises from the biological treatment of
depression. Antidepressants with alpha-adrenergic, anti-
cholinergic and anti-histaminic activities or electro-con-
vulsive therapy may cause significant cognitive impair-
ment. However, the impact of medication appears to be
mild and with doubtful clinical significance (Gorenstein
et al. 2006). The problem is even more relevant for anxiety
patients using benzodiazepines. The review done by
Stewart (2005) showed that benzodiazepines produce
cognitive dysfunctions in patients treated for longer periods
and that the cognitive impairment may be preserved after
the benzodiazepine withdrawal.
Cognitive deficits in anxiety disorders
Comparable deficits in this domain are present also in
anxiety disorders (Hindmarch 1998). In anxiety disorders,
it is proposed that cognitive impairment is a primary
symptom, although it is well known that drugs, especially
benzodiazepines interfere with cognition, too. The impact
of anxiety on cognitive functioning is however less
explored than in other disorders including depression
(Jakuszkowiak-Wojten et al. 2013). Some early studies of
this subject showed even no cognitive deficits in such
conditions like panic disorder and social phobia (Gladsjo
et al. 1998). However, according to other authors,
reduced performance in panic disorder and social phobia
patients, relative to control subjects, are found in the
domains of verbal learning and memory (Asmundson
et al. 1995). An intentional bias toward negatively–val-
enced verbal stimuli and longer decision-making latencies
were observed by the authors of the study performed on
subjects suffering from panic disorder (Kaplan et al.
2006). In another research project related to this group of
patients, deficits in delayed visual memory and recogni-
tion test in CANTAB test were found (Raczak et al.
2013).
Objective of the analysis
There is an increasing number of data from literature
showing that those cognitive deficits present in depressive
and anxiety patients may decrease as a result of successful
treatment. The objective of our analysis is to find out the
impact of different pharmacological and psychological
methods of treatment of depressive and anxiety disorders
on the cognitive functioning in affected patients. The focus
of this review was on studies on depression and anxiety
disorders (1990–2014). We searched PubMed using the
following search terms [effective date: 12th March 2014):
(depression (Title/Abstract) OR anxiety (Title/Abstract)]
AND pharmacotherapy (Title/Abstract) OR psychotherapy
OR cognitive functions OR memory OR attention OR
executive functions AND psychomotor speed AND Eng-
lish (lang) AND (1990/01/01(PDAT): 2014/03/12(PDAT)).
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Impact of pharmacological treatment of depressive
and anxiety disorders on cognition
The number of studies referring to the impact of pharma-
cological treatment of depressive and anxiety disorders on
cognition is growing, however they still bring inconsistent
results. Table 1.
A relationship between the improvement of cognitive
functioning as a result of antidepressant drugs was
observed in a group of 50 patients treated with fluoxetine
and reboxetine. Partial improvement in attention and
memory was achieved, and no differences between patients
treated with fluoxetine and reboxetine were found (Galassi
et al. 2006). In other studies escitalopram and duloxetine
improved the deficits of attention and executive functions
(Herrera-Guzma´n et al. 2010), as well as memory and
mental processing speed (Herrera-Guzma´n et al. 2009).
Some reports confirm the positive impact of sertraline on
cognition in patients with depressive and anxiety disorders
(Constant et al. 2005; Schrijvers et al. 2009). In our own
study we observed that a 3-month treatment with tianeptine
led to the improvement of attention and short-term memory
in patients with mild and moderate depression (Klasik et al.
2011). On the other hand, in a 12-month study performed
on a group of 281 old depressive patients aged 65 and
older, antidepressant effect of citalopram, sertraline or
paroxetine was not related to the improvement of cognitive
symptoms (Han et al. 2011). Antidepressants were also
found non-effective in the treatment of cognitive dys-
functions. The attempts to find any specific intervention to
improve the cognitive symptoms in depression are prom-
ising. One of the agent is S-adenosyl methionine (SAMe).
The naturally existing molecule may hypothetically mod-
ulate the neurotransmitter metabolism and improve the
cognition in MDD (Krzystanek et al. 2011). In one of the
recent studies, SAMe was added to the treatment with
serotonin re-uptake inhibitor in 46 MDD non-responders
(Levkovitz et al. 2012). It was found that SAMe improves
the ability to recall information in the studied group. Tal-
arowska et al. (2012) examined the total antioxidant status
(TAS) in depressive patients and she found that the higher
the concentration of TAS in plasma of depressive patient
is, the higher both the severity of depression and the
impairment of short- and long-term declarative memory,
working memory and verbal fluency are. Another study of
149 MDD patients revealed that cognitive performance, as
well as treatment response in depressive patients, correlate
with plasma CRP levels (Chang et al. 2012). Results of
such studies may imply that anti-inflammatory drugs, as the
adjunctive treatment, may play a role in preservation and/
or improvement of cognition in depressive patients. A
similar example is the use of minocycline—neuroprotec-
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Pae et al. (2008) that minocycline may be effective for
augmentation of antidepressants in the treatment of cog-
nitive disfunctions in MDD. Another approach to identify
the agents, producing specific improvement of cognition in
depressive and anxiety patients is a use of sigma-1 receptor
agonist. From this point of view, very interesting is the
attempt to use fluvoxamine, the potent sigma-1 receptor
agonist. Fluvoxamine was proved in animal models and in
human studies to improve the cognitive impairments
(Hindmarch and Hashimoto 2010). Borkowska et al. (2007)
reported the specific pro-cognitive effect of mirtazapine in
improving cognitive impairment in unipolar depression. It
is worth noticing that the improvement of cognition does
not correlate with recovery from depressive symptoms and
it occurred after 3 months of the mirtazapine treatment.
After 6 months of the treatment, patients achieved the
cognitive test results comparable with healthy controls. In
one study also donepezil was found to improve the cog-
nitive impairment in depressive patients aged 50 or more
(Pelton et al. 2008). Donepezil in this study was added to
the ongoing treatment with antidepressant. Raskin et al.
(2007) studied the influence of duloxetine on cognitive
deficits in MDD elderly patients. The study was done in
considerable number of patients and revealed that duloxe-
tine can significantly improve memory and verbal learning.
Another small sample study with captopril and enalapril,
angiotensin converting enzyme inhibitors, showed the
antihypertensive drugs can improve cognition in non-
depressive subjects (Braszko et al. 2003).
It is too early to draw any conclusions from the studies
on the relation between the antidepressants and cognitive
impairment in unipolar depression. Especially in anxiety
disorders the studies are less than few and the field requires
further exploration. Many more studies are necessary to
establish the real impact of antidepressants on cognition, as
well as to discriminate the negative influence of some
antidepressants on cognition and to create new drug strat-
egies for improvement of the cognitive impairment in
depression and anxiety.
Impact of psychological treatment methods of cognitive
impairment in depression and anxiety disorders
Except for pharmacology there is a number of non-bio-
logical interventions which may directly or indirectly lead
to cognitive improvement in depressed patients. One group
are interventions, whose primary goal is a cognitive
training as a cognitive remediation. And the other group
includes the traditional methods of psychotherapy, like
psychodynamic psychotherapy, CBT, interpersonal psy-
chotherapy, for which the main goal is the improvement of
patient‘s clinical symptoms. The impact on neurocognition
may be an additional value of the therapeutic interventions.
Role of cognitive training methods
The usefulness of the cognitive remediation was confirmed
in a number of studies. Elgamal et al. (2007) observed a
positive impact of cognitive training on attention, verbal
learning and memory, psychomotor speed and executive
function in recurrent major depressive disorder. Naismith
et al. (2010) observed improvement in memory perfor-
mance in patients with affective disorders. Bowie et al.
(2013a) confirmed a positive impact of daily online cog-
nitive exercises on such domains like attention/processing
speed and verbal memory in patients with treatment-
resistant depression. The authors of the above study ana-
lyze and emphasize the advantages on cognitive remedia-
tion trainings in mood disorders in their review (Bowie
et al. 2013b).
Neuroimaging studies evidence of the psychotherapy
effectiveness in cognitive improvement
Depressive disorders
In literature we can find an increasing number of studies
analyzing the neurobiological basis of psychotherapy (de
Vries et al. 2013), however the research data are still not
consistent and valuable, as the number of studies is still
small and they differ in methodology and evaluated treat-
ment strategies (Karch et al. 2012). Some of the adopted
methods of analyzing the impact of psychotherapy on brain
functioning are neuroimaging techniques. Modulation of
limbic and cortical regions was observed in patients with
unipolar depression treated with CBT (Goldapple et al.
2004). In some studies certain differences in the effect of
both treatment methods are reported. The study comparing
the results of the treatment with CBT and venlafaxine in a
group of patients with major depressive disorder, revealed
that CBT modulates cortical-limbic connectivity and that
venlafaxine engages additional cortical and striatal regions
(Kennedy et al. 2007).
Anxiety disorders
It was found that cognitive-behavioral therapy of panic dis-
order reduces the hyperactivity in several brain areas causing
adaptive metabolic changes of the medial prefrontal cortex
(Sakai et al. 2006). Similar changes were found after the
treatment either with CBT or with antidepressants in patients
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suffering from panic disorder (Prasko et al. 2004) or from
social phobia (Furmark et al. 2002).
Importance of methodological limitations
The field of neuroimaging studies confirming the effects of
psychotherapy on modulation of functioning on different
structures of the brain is still growing, bringing more and
more findings (Lindauer et al. 2008; Buchheim et al. 2012;
Cervenka et al. 2012; Gawrysiak et al. 2013; Goldin et al.
2013; Morgie`ve et al. 2013; Schiepek et al. 2013) Recent
advances in this filed were reviewed by Barsaglini et al.
2013. The authors conclude that the impact of psycho-
therapy on measurable changes in the brain is beyond
doubt, but it appears to be dependent on the investigated
disorder and the type of the therapy used. Messina et al.
(2013) in their meta-analysis also confirm positive neural
changes in brain networks associated to emotion regulation
after psychotherapy of depression and anxiety drawing the
attention to methodological limitations like small sizes,
lack of suitable control groups, heterogeneity of techniques
or study designs.
Neuropsychological studies evidence of the beneficial
effect of psychotherapy on cognition
Contrary to the results of neuroimaging studies, the
access to research data related to the neuropsychological
evaluation of cognitive changes occurring in the process
of psychotherapy is very limited. This also refers to
studies comparing the cognitive functioning in patients
treated with psychotherapy and pharmacotherapy.
Table 2.
In a recent study performed in Brasil 272 patients aged
26–34 were examined. They were randomly divided in
three subgroups. The first subgroup was treated with
long-term psychodynamic psychotherapy, the second with
fluoxetine, and the third received both psychotherapeutic
and pharmacological treatment. The intensity of depres-
sion was evaluated with the use of Beck Depression
Inventory (BDI), and the neurocognitive deficits assessed
with the Wechsler adult intelligence scale, third edition
(WAIS-III). The study lasted 2 years, and the neuropsy-
chological examination was repeated every six months.
Patients treated with the combination of psychodynamic
psychotherapy and fluoxetine presented the greatest
improvement in cognitive scores at the end of the study.
The lowest improvement was observed in the group of
patients treated with fluoxetine (Bastos et al. 2013). The
results of this study were similar to our own. However,
the number of patients participating in our research pro-
ject was smaller, we recruited 60 patients with a diag-
nosis of recurrent depressive disorder. They were also
divided into three subgroups treated with pharmacother-
apy with sertraline, psychodynamic psychotherapy or
both. The neuropsychological changes occurring during
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the treatment process were assessed with the Vienna Test
System (VTS). In comparison to the Brasilian study, the
time of observation was much shorter (8 weeks). The
improvement in short-term memory and attention was
also the most prominent in patients treated with both
forms of therapy. However, contrary to the results of the
Brasilian study, the worst performing group consisted of
patients was treated with psychotherapy alone (Klasik
et al. 2012). What is the mechanism of information
processing during the psychodynamic therapeutic process,
still remains unclear. Novac (2013) proposed the use of a
term ‘‘transprocessing’’ illustrating the discussed phe-
nomena. This term is a combination of two terms. The
first term is transduction, which is reexpression and
translation of a functional brain activity into a new type
activity, like transduction of stress in the function of the
hypothalamopituitary axis. The second term is processing,
a function by which the brain makes sense of environ-
mental inputs. According to the author, changes in these
processes during psychotherapy are internalized and
assimilated. A small number of studies analyze the
influence of Cognitive-Behavioral Therapy (CBT) on
neurocognition. Reinecke et al. (2013) performed a study
on a group of 28 patients with panic disorder. Attention
visual probe task was performed a day after the treatment
session and 4 weeks later. The authors observed the
decrease of vigilance for threat information in the treated
group, and the magnitude of this early effect predicted
therapeutic response. There is also evidence from litera-
ture that psychotherapy may improve neurocognition in
depressive disorders related to a psychoorganic condition.
Mackin et al. (2013) observed a beneficial effect of
psychotherapy on cognitive functioning after psycho-
therapy treatment of depression in older adults with
executive dysfunction. Dobkin et al. (2014) described a
neuropsychological improvement in patients with Par-
kinson’s disease after cognitive-behavioral treatment of
depression. Improvements in verbal memory and execu-
tive functioning were observed after 10-week treatment
period. Collerton (2013) proposed the explanation of
possible structural and functional brain changes after
CBT psychotherapy treatment related to neuroplasticity in
the linked systems of the frontal, cingulate, and limbic
cortex. Except from the theories aiming at the explana-
tion of psychotherapy effects, efforts are also made to
analyze the interaction of combined pharmacological and
psychological interventions. An interesting approach was
presented by Castre´n (2013), proposing a hypothesis that
antidepressant agents reactivate juvenile-like plasticity in
the cortex, which facilitates further recovery of neuronal
networks related to psychotherapy and other non-phar-
macological interventions in mood disorders.
Conclusions
Deficits in neurocognition play a significant role among
other symptoms of depressive and anxiety disorders. It is
important for the clinicians to what extent the commonly
used methods of treatment of these conditions exert a
positive influence on cognitive processes. The results of
studies using pharmacological treatment are inconsistent.
There is a group of research findings suggesting a favorable
effect of antidepressive treatment on this domain of
symptoms (Galassi et al. 2006; Borkowska et al. (2007);
Herrera-Guzma´n et al. 2009, 2010; Klasik et al. 2011).
Other data from literature suggest no cognitive improve-
ment following treatment of antidepressants (Han et al.
2011). Efforts are made to introduce other types of phar-
macotherapy in order to reach the expected goal, like the
use of donepezil (Pelton et al. 2008) or captopril and
enalapril (Braszko et al. 2003), S-adenosyl methionine
(SAMe) (Krzystanek et al. 2011; Levkovitz et al. 2012).
Anyway, the studies on the impact of antidepressant
medication on cognitive functioning in depression and
anxiety patients are still insufficient in number and they do
not allow to come to any final conclusion about its effec-
tiveness towards the cognitive impairment in depression.
On the other hand, an increasing interest of the researches
is focused on the impact of non-biological treatment
methods on this domain of symptoms. This interest is
enhanced by a growing data from neuroimaging studies
confirming the impact of functional changes in brain
structures following psychotherapeutic process (Barsaglini
et al. 2013; Messina et al. 2013). Some reports confirm the
positive effect of different psychotherapeutic treatment
methods on the improvement of cognitive skills alongside
with clinical improvement (Klasik et al. 2012; Bastos et al.
2013; Reinecke et al. 2013; Dobkin et al. 2014). The above
studies are small in number and do not allow to draw
unequivocal conclusions. What is however suggested by
research study results in this field, psychotherapy and
pharmacotherapy used in combination may be more
effective than each of those methods used alone (Klasik
et al. 2012; Bastos et al. 2013, Castre´n 2013).
The above analysis suggests that the commonly used
pharmacological and non-pharmacological treatment
strategies targeted to help patients suffering from depres-
sive and anxiety disorders may have a positive influence
non only on clinical symptoms of those conditions, but also
on patients‘ cognitive functioning. Because of a relatively
small number of studies and different methodological
attitudes, we still need to continue our research in order to
explain discussed phenomenon more profoundly. Except
for the widely used treatment methods like pharmacother-
apy and psychotherapy, additional techniques of cognitive
Impact of pharmacological and psychological treatment methods S107
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enhancement should be used in the treatment process, both
biological, like e.g. transcranial magnetic stimulation
techniques (Balconi 2013), and non-biological, like cog-
nitive training (Elgamal et al. 2007; Naismith et al. 2010;
Bowie et al. 2013a).
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